An Effective Hypoxia-Related Long Non-Coding RNAs Assessment Model for Prognosis of Clear Cell Renal Carcinoma

Abstract

Hypoxia is a significant clinical feature and regulates various tumor processes in clear cell renal carcinoma (ccRCC). Increasing evidence has demonstrated that long non-coding RNAs (lncRNAs) are closely associated with the survival outcomes of ccRCC patients and regulates hypoxia-induced tumor processes. Thus, this study aimed to develop a hypoxia-related lncRNA (HRL) prognostic model for predicting the survival outcomes in ccRCC. LncRNAs in ccRCC samples were extracted from The Cancer Genome Atlas database. Hypoxia-related genes were downloaded from the Molecular Signatures Database. A co-expression analysis between differentially expressed lncRNAs and hypoxia-related genes in ccRCC samples was performed to identify HRLs. Univariate and multivariate Cox regression analyses were performed to select nine optimal lncRNAs for developing the HRL model. The prognostic model showed good performance in predicting prognosis among patients with ccRCC, and the validation sets reached consistent results. The model was also found to be related to the clinicopathologic parameters of tumor grade and tumor stage and to tumor immune infiltration. In conclusion, our findings indicate that the hypoxia-lncRNA assessment model may be useful for prognostication in ccRCC cases. Furthermore, the nine HRLs included in the model might be useful targets for investigating the tumorigenesis of ccRCC and designing individualized treatment strategies.

A Metastasis-Related lncRNA Signature Correlates With the Prognosis in Clear Cell Renal Cell Carcinoma

“…MAPK pathway is key signaling pathway that conducts extracellular signal through tertiary kinase cascade and regulates many physiological processes, such as cell growth, apoptosis and death. MAPK pathway is also of great significance in the malignant progression of tumor ( 28 ). TGF-β and Wnt signaling pathways are classical signaling pathways that activate EMT and promote tumor progression.…”

A Novel Assessment Model Based on Molecular Subtypes of Hypoxia-Related LncRNAs for Prognosis of Bladder Cancer

“…The rise of biological big data mining for patient prognosis has promoted the rapid development of precision medicine in recent years (Mollayeva et al, 2019). Previous studies have performed HRL analyses for multiple types of tumors and built prognostic models, including clear cell renal carcinoma (Zhang et al, 2021) Immune checkpoint inhibitors are a potential treatment for cancer therapy that block key molecules and have shown impressive efficacy against cancer, especially revolutionizing the management of metastatic and locally advanced BCa (de Kouchkovsky et al, 2021;Sun et al, 2021b). In the multifaceted immune regulation of BCa, CTLA4 is one of the primary immune checkpoints.…”

Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity?

“…Studies in cancer patient cohorts have similarly correlated the presence of hypoxia with an immunosuppressed TME in breast cancer, 45 , 46 clear cell renal cell carcinoma, 47 colorectal cancer, 48 hepatocellular carcinoma, 49–51 melanoma, 52 osteosarcoma, 53 neuroblastoma 43 and pancreatic cancer, 41 , 54 among others. 55 These studies used hypoxia gene signatures to determine the hypoxic state and immune fraction or gene set enrichment analysis to highlight the immune microenvironment.…”